Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
146
-
Total 13F shares, excl. options
-
54.4M
-
Shares change
-
+1.49M
-
Total reported value, excl. options
-
$1.06B
-
Value change
-
+$30M
-
Put/Call ratio
-
0.36
-
Number of buys
-
62
-
Number of sells
-
-67
-
Price
-
$19.50
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2022
177 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 146 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.4M shares
of 105M outstanding shares and own 51.98% of the company stock.
Largest 10 shareholders include JPMORGAN CHASE & CO (6.82M shares), BlackRock Inc. (5.29M shares), Palo Alto Investors LP (4.42M shares), VANGUARD GROUP INC (3.65M shares), Capital World Investors (3.35M shares), Polar Capital Holdings Plc (2.46M shares), JENNISON ASSOCIATES LLC (2.44M shares), FRANKLIN RESOURCES INC (2.21M shares), Capital International Investors (1.55M shares), and STATE STREET CORP (1.54M shares).
This table shows the top 146 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.